Europe's pharmaceutical majors managed to post decent financials for the second quarter of 2022 and did not seem overly concerned about the rise in rhetoric across the Atlantic concerning future US drug pricing rises. The tough macro-economic backdrop, with inflation on the rise and recessions looming across the continent, failed to have much of an impact either.
At Novartis AG, chief financial officer Harry Kirsch addressed growing concerns about the prospect of a global recession, noting...